Table 4. Budgetary impact (US$) of the scenarios evaluated and incremental costs (ranibizumab alone; bevacizumab alone), 2008–2011, Brazil.
Year | Reference Scenario | Costs, ranibizumab alone | Incremental cost, ranibizumab | Costs, bevacizumab alone | Incremental cost bevacizumab |
---|---|---|---|---|---|
2008 | 1,443,676,107.00 | 3,076,414,450.00 | 1,632,738,343.00 | 127,850,362.00 | (1,315,825,745.00) |
2009 | 1,304,484,526.00 | 3,203,310,999.00 | 1,898,826,473.00 | 133,123,959.00 | (1,171,360,567.00) |
2010 | 1,436,566,306.00 | 3,364,862,918.00 | 1,928,296,612.00 | 139,837,772.00 | (1,296,728,534.00) |
2011 | 1,335,237,773.00 | 3,388,648,570.00 | 2,053,410,796.00 | 140,826,261.00 | (1,194,411,511.00) |
Total | 5,519,964,714.00 | 13,033,236,939.00 | 1,878,318,056.00 | 541,638,354.00 | (4,978,326,359.00) |
1 real = US$2.00.